HECTORNCT05068674
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2028 to Oct 2029
- Eligibility criteria shortened, about 2 words
- Notable Primary and study completion dates: Oct 2025 to Oct 2028v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Mar 2022 to Mar 22, 2022
- Minor Start date: Jan 2022 to Mar 2022
- Collaborators expanded, about 6 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The maximum tolerated dose (MTD) among 3 dose levels of allogeneic human embryonic stem cell-derived cardiomyocytes (hESC-CMs)
Timeframe: 3 Years
Arms and interventions
Cohort 1Active comparator
Low dose (50M cells)
Cohort 2Active comparator
Medium dose (150M cells)
Cohort 3Active comparator
High dose (300M cells)
Drugs: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Sites
1 site in 1 country
- Stanford Hospital and ClinicsPalo Alto, California, United States